BUSINESS

• Roche’s Diagnostic Gets Japan Coverage to Identify HER2 Low Breast Cancer Patients Eligible for Enhertu
  May 10, 2023

• Trulicity Shipment Control Continues, Lilly Calls for Use of Novo Drugs
  May 10, 2023

• Eisai Cuts FY2022 Earnings Forecast on FX, Subpar Mainstay Results
  May 10, 2023

• Opdivo Best-Selling Med in Japan for 16 Months Straight: Encise
  May 10, 2023

• PeptiDream Unit Seeks Label Expansion for PET Diagnostic Amyvid
  May 9, 2023

• Over 40% of Japan Drug Makers Allow Side Jobs, MSD Has Largest 188 Staffers Tapping Option: Poll
  May 9, 2023

• Eisai, BlissBio to Codevelop ADC Using Eribulin
  May 9, 2023

• Sumitomo Gears Up for Post-Latuda Growth, Sets 2027 Target Sales to 600 Billion Yen
  May 8, 2023

• Sumitomo’s Projected Operating Loss Widens on Ditched Cancer Med, US Realignment
  May 8, 2023

• Astellas Looks at Iveric Bio’s Eye Drug as 3rd Biz Pillar to Counter Xtandi Cliff
  May 8, 2023

• Astellas to Snap Up Iveric Bio for US$5.9 Billion
  May 1, 2023

• Meiji Files CSL Seqirus’ mRNA COVID Vaccine in Japan
  May 1, 2023

• FDA Accepts BLA Re-Submission for Takeda’s Entyvio SC
  May 1, 2023

• FDA Approves 2-Month Long-Acting Abilify: Otsuka/Lundbeck
  May 1, 2023

• Takeda Files TAK-662 for Congenital Protein C Deficiency in Japan
  May 1, 2023

• Astellas Logs 17.2% Sales Growth in FY2022 on Xtandi, but Profits Fall
  April 28, 2023

• Daiichi Sankyo on Path to Net 2 Trillion Yen in Sales by FY2025 on Robust Core Products
  April 28, 2023

• Chugai’s Q1 Profit Drops by Half in Pullback from Alexion Settlement Gain
  April 28, 2023

• Astellas to Promote HR Chief Katsuyoshi Sugita to EVP
  April 28, 2023

• Taiho’s Futibatinib Nabs EU Panel Backing for Bile Duct Cancer
  April 28, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 137
• 138
• 139
• 140
• 141
• 142
• 143
• 144
• 145
• …
• Next ›
• 最終 »